Lotus Pharmaceutical (Taiwan) Performance
| 1795 Stock | TWD 256.50 1.50 0.58% |
The company secures a Beta (Market Risk) of 0.51, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Lotus Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Lotus Pharmaceutical is expected to be smaller as well. At this point, Lotus Pharmaceutical has a negative expected return of -0.0033%. Please make sure to verify Lotus Pharmaceutical's treynor ratio, potential upside, and the relationship between the total risk alpha and maximum drawdown , to decide if Lotus Pharmaceutical performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Lotus Pharmaceutical Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Lotus Pharmaceutical is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
| Begin Period Cash Flow | 1.5 B | |
| Total Cashflows From Investing Activities | -1.6 B |
Lotus |
Lotus Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 26,000 in Lotus Pharmaceutical Co on October 24, 2024 and sell it today you would lose (350.00) from holding Lotus Pharmaceutical Co or give up 1.35% of portfolio value over 90 days. Lotus Pharmaceutical Co is generating negative expected returns and assumes 1.9523% volatility on return distribution over the 90 days horizon. Simply put, 17% of stocks are less volatile than Lotus, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Lotus Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lotus Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lotus Pharmaceutical Co, and traders can use it to determine the average amount a Lotus Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0017
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 1795 |
Estimated Market Risk
| 1.95 actual daily | 17 83% of assets are more volatile |
Expected Return
| 0.0 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lotus Pharmaceutical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lotus Pharmaceutical by adding Lotus Pharmaceutical to a well-diversified portfolio.
Lotus Pharmaceutical Fundamentals Growth
Lotus Stock prices reflect investors' perceptions of the future prospects and financial health of Lotus Pharmaceutical, and Lotus Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lotus Stock performance.
| Return On Equity | 0.26 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.31 % | |||
| Current Valuation | 73.53 B | |||
| Shares Outstanding | 262.04 M | |||
| Price To Earning | 16.94 X | |||
| Price To Book | 4.97 X | |||
| Price To Sales | 4.31 X | |||
| Revenue | 12.65 B | |||
| EBITDA | 2.93 B | |||
| Cash And Equivalents | 1.97 B | |||
| Cash Per Share | 8.02 X | |||
| Total Debt | 4.67 B | |||
| Debt To Equity | 0.82 % | |||
| Book Value Per Share | 51.30 X | |||
| Cash Flow From Operations | 119.66 M | |||
| Earnings Per Share | 11.86 X | |||
| Total Asset | 21.22 B | |||
About Lotus Pharmaceutical Performance
Evaluating Lotus Pharmaceutical's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Lotus Pharmaceutical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lotus Pharmaceutical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Lotus Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells medicines in Taiwan, Korea, the United States, and internationally. Lotus Pharmaceutical Co., Ltd. is a subsidiary of Alvogen Emerging Markets Holdings Limited. LOTUS PHARMACEUTICAL operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan Stock Exchange.Things to note about Lotus Pharmaceutical performance evaluation
Checking the ongoing alerts about Lotus Pharmaceutical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lotus Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lotus Pharmaceutical generated a negative expected return over the last 90 days | |
| About 62.0% of the company shares are owned by insiders or employees |
- Analyzing Lotus Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lotus Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Lotus Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lotus Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lotus Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lotus Pharmaceutical's stock. These opinions can provide insight into Lotus Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Lotus Stock Analysis
When running Lotus Pharmaceutical's price analysis, check to measure Lotus Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lotus Pharmaceutical is operating at the current time. Most of Lotus Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Lotus Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lotus Pharmaceutical's price. Additionally, you may evaluate how the addition of Lotus Pharmaceutical to your portfolios can decrease your overall portfolio volatility.